Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of inhalation of tiotropium once daily 18 mcg versus salmeterol twice daily 50 mcg on time to first exacerbation in COPD [chronic obstructive pulmonary disease] patients (a randomized, double-blind, double-dummy, parallel group, one-year study).

Trial Profile

Effect of inhalation of tiotropium once daily 18 mcg versus salmeterol twice daily 50 mcg on time to first exacerbation in COPD [chronic obstructive pulmonary disease] patients (a randomized, double-blind, double-dummy, parallel group, one-year study).

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Tiotropium bromide (Primary) ; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms POET; POET-COPD
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 14 Jun 2012 Results of a German cost-effectiveness analysis published in the European Respiratory Journal.
    • 28 Sep 2011 Results of an economic analysis presented at the 21st Annual Congress of the European Respiratory Society.
    • 25 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top